Ludwig Kappos

Summary

Affiliation: University Hospital
Country: Switzerland

Publications

  1. ncbi request reprint Towards a european network for multiple sclerosis trials (ENMST)
    L Kappos
    Outpatient Clinic Neurology Neurosurgery, University Hospitals, Basel, Switzerland
    Mult Scler 9:627-9. 2003
  2. ncbi request reprint 10 years of interferon beta-1b (Beta feron therapy
    Ludwig Kappos
    Outpatient Clinic Neurology Neurosurgery, University Hospital, Petersgraben 4, 4031 Basel, Switzerland
    J Neurol 252:iii1-iii2. 2005
  3. ncbi request reprint Genomics and proteomics: role in the management of multiple sclerosis
    Ludwig Kappos
    Outpatient Clinic Neurology Neurosurgery, University Hospital, Petersgraben 4, 4031 Basel, Switzerland
    J Neurol 252:iii21-iii27. 2005
  4. ncbi request reprint Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS
    L Kappos
    University of Basel, Basel, Switzerland
    Neurology 67:944-53. 2006
  5. doi request reprint Effect of BG-12 on contrast-enhanced lesions in patients with relapsing--remitting multiple sclerosis: subgroup analyses from the phase 2b study
    Ludwig Kappos
    Department of Neurology, University Hospital Basel, Basel, Switzerland
    Mult Scler 18:314-21. 2012
  6. doi request reprint Long-term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial
    Ludwig Kappos
    From the Department of Neurology L K, University Hospital, Basel, Switzerland St Michael s Hospital P O C, Toronto, Canada Medical Image Analysis Centre E W R, University Hospital, University of Basel, Switzerland Department of Neurology C P, VU University Medical Center, Amsterdam, Netherlands Ludwig Maximilians University of Munich and Munich Cluster for Systems Neurology SyNergy R H, Germany Department of Neurology K S, Medical University of Lodz, Poland Novartis Pharmaceuticals Corporation S R, G F, East Hanover, NJ and Novartis Pharma AG R S, P V R, L Z A, Basel, Switzerland
    Neurology 84:1582-91. 2015
  7. pmc Patient subgroup analyses of the treatment effect of subcutaneous interferon β-1a on development of multiple sclerosis in the randomized controlled REFLEX study
    Mark S Freedman
    Department of Medicine, University of Ottawa, 501 Smyth Road, Ottawa, ON, K1H 8L6, Canada
    J Neurol 261:490-9. 2014
  8. pmc Variability in detection and quantification of interferon β-1b-induced neutralizing antibodies
    Hans Peter Hartung
    Heinrich Heine Universitat, Moorenstraße 5, Dusseldorf 40225, Germany
    J Neuroinflammation 9:129. 2012
  9. pmc Clinical effects of natalizumab on multiple sclerosis appear early in treatment course
    Ludwig Kappos
    Departments of Neurology and Biomedicine, University Hospital Basel, Petersgraben 4, Basel, Switzerland
    J Neurol 260:1388-95. 2013
  10. pmc Modeling the cumulative genetic risk for multiple sclerosis from genome-wide association data
    Joanne H Wang
    Department of Neurology, University of California San Francisco, San Francisco, CA 94143 0435, USA
    Genome Med 3:3. 2011

Detail Information

Publications149 found, 100 shown here

  1. ncbi request reprint Towards a european network for multiple sclerosis trials (ENMST)
    L Kappos
    Outpatient Clinic Neurology Neurosurgery, University Hospitals, Basel, Switzerland
    Mult Scler 9:627-9. 2003
    ..Collaboration with existing international organizations and institutions, especially the Sylvia Lawry Centre for MS Research, as well as with similar initiatives in North America and other parts of the world is envisaged...
  2. ncbi request reprint 10 years of interferon beta-1b (Beta feron therapy
    Ludwig Kappos
    Outpatient Clinic Neurology Neurosurgery, University Hospital, Petersgraben 4, 4031 Basel, Switzerland
    J Neurol 252:iii1-iii2. 2005
  3. ncbi request reprint Genomics and proteomics: role in the management of multiple sclerosis
    Ludwig Kappos
    Outpatient Clinic Neurology Neurosurgery, University Hospital, Petersgraben 4, 4031 Basel, Switzerland
    J Neurol 252:iii21-iii27. 2005
    ..These data may help us approach the goal of a really "individualised therapy" with increased efficacy, reduced adverse drug reactions and more efficient use of health care resources...
  4. ncbi request reprint Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS
    L Kappos
    University of Basel, Basel, Switzerland
    Neurology 67:944-53. 2006
    ..c.) interferon (IFN) beta-1a in relapsing-remitting multiple sclerosis (RRMS)...
  5. doi request reprint Effect of BG-12 on contrast-enhanced lesions in patients with relapsing--remitting multiple sclerosis: subgroup analyses from the phase 2b study
    Ludwig Kappos
    Department of Neurology, University Hospital Basel, Basel, Switzerland
    Mult Scler 18:314-21. 2012
    ....
  6. doi request reprint Long-term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial
    Ludwig Kappos
    From the Department of Neurology L K, University Hospital, Basel, Switzerland St Michael s Hospital P O C, Toronto, Canada Medical Image Analysis Centre E W R, University Hospital, University of Basel, Switzerland Department of Neurology C P, VU University Medical Center, Amsterdam, Netherlands Ludwig Maximilians University of Munich and Munich Cluster for Systems Neurology SyNergy R H, Germany Department of Neurology K S, Medical University of Lodz, Poland Novartis Pharmaceuticals Corporation S R, G F, East Hanover, NJ and Novartis Pharma AG R S, P V R, L Z A, Basel, Switzerland
    Neurology 84:1582-91. 2015
    ..To assess long-term safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (RRMS)...
  7. pmc Patient subgroup analyses of the treatment effect of subcutaneous interferon β-1a on development of multiple sclerosis in the randomized controlled REFLEX study
    Mark S Freedman
    Department of Medicine, University of Ottawa, 501 Smyth Road, Ottawa, ON, K1H 8L6, Canada
    J Neurol 261:490-9. 2014
    ..The effect of sc IFN β-1a was not substantially influenced by baseline patient demographic and disease characteristics, or baseline presence/absence of McDonald 2010 MS...
  8. pmc Variability in detection and quantification of interferon β-1b-induced neutralizing antibodies
    Hans Peter Hartung
    Heinrich Heine Universitat, Moorenstraße 5, Dusseldorf 40225, Germany
    J Neuroinflammation 9:129. 2012
    ..Interferon-beta (IFNB) therapy for multiple sclerosis can lead to the induction of neutralizing antibodies (NAbs) against IFNB. Various methods are used for detection and quantification of NAbs...
  9. pmc Clinical effects of natalizumab on multiple sclerosis appear early in treatment course
    Ludwig Kappos
    Departments of Neurology and Biomedicine, University Hospital Basel, Petersgraben 4, Basel, Switzerland
    J Neurol 260:1388-95. 2013
    ..Natalizumab resulted in rapid, sustained reductions in disease activity in both AFFIRM and in clinical practice. This decrease in disease activity occurred within the first 3 months of treatment even in patients with more active disease...
  10. pmc Modeling the cumulative genetic risk for multiple sclerosis from genome-wide association data
    Joanne H Wang
    Department of Neurology, University of California San Francisco, San Francisco, CA 94143 0435, USA
    Genome Med 3:3. 2011
    ..Nevertheless, the knowledge of MS genetics remains incomplete, with many risk alleles still to be revealed...
  11. doi request reprint A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis
    Ludwig Kappos
    Department of Neurology, University Hospital, University of Basel, Switzerland
    N Engl J Med 362:387-401. 2010
    ....
  12. ncbi request reprint Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials
    L Kappos
    Outpatient Clinic Neurology Neurosurgery, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland
    Neurology 63:1779-87. 2004
    ..Reasons for this discrepancy were explored in the combined dataset...
  13. doi request reprint Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
    Ludwig Kappos
    University Hospital, Basel, Switzerland
    Lancet 378:1779-87. 2011
    ..We aimed to assess efficacy and safety of two dose regimens of the humanised anti-CD20 monoclonal antibody ocrelizumab in patients with relapsing-remitting multiple sclerosis...
  14. ncbi request reprint Effect of drugs in secondary disease progression in patients with multiple sclerosis
    Ludwig Kappos
    Departments of Neurology and Research, University Hospitals, Kantonsspital, Petersgraben 4, CH 4031 Basel, Switzerland
    Mult Scler 10:S46-54; discussion S54-5. 2004
    ..The risk-benefit ratio of these cytostatic agents remains controversial. New strategies addressing the important neurodegenerative aspects of the disease are urgently needed...
  15. ncbi request reprint Interferons in multiple sclerosis
    Ludwig Kappos
    Department of Neurology, University Hospitals, Kantonsspital, CH 4031 Basel, Switzerland
    Neurol Clin 23:189-214, vii-viii. 2005
  16. doi request reprint Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring
    Ludwig Kappos
    University Hospital, Basel, Switzerland
    Lancet Neurol 10:745-58. 2011
    ....
  17. ncbi request reprint Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study
    Ludwig Kappos
    Neurology and Department of Research, University Hospital, Basel, Switzerland
    Lancet 370:389-97. 2007
    ..Our aim was to determine whether early initiation of treatment with interferon beta prevents development of confirmed disability in MS...
  18. ncbi request reprint Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study
    L Kappos
    Department of Neurology and Research, University Hospital Basel, Switzerland
    Neurology 65:40-7. 2005
    ..To determine the incidence and clinical significance of neutralizing antibody (NAb) formation in patients with relapsing multiple sclerosis (MS) who participated in the European Interferon Beta-1a IM Dose-Comparison Study...
  19. doi request reprint Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial
    Ludwig Kappos
    University Hospital, Basel, Switzerland
    Lancet Neurol 8:987-97. 2009
    ..The 5-year active treatment extension compares the effects of early and delayed treatment with interferon beta-1b on time to clinically definite multiple sclerosis (CDMS) and other disease outcomes, including disability progression...
  20. ncbi request reprint Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring
    Ludwig Kappos
    University Hospital, Basel, Switzerland
    Lancet Neurol 6:431-41. 2007
    ..Maintaining clinical vigilance allows for early suspension of natalizumab in potential cases of PML, thereby increasing the opportunity for immune reconstitution, which may improve prognosis if PML is confirmed...
  21. ncbi request reprint Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes
    L Kappos
    University Hospital, Basel, Switzerland
    Neurology 67:1242-9. 2006
    ..To assess efficacy, safety, and tolerability of every-other-day interferon beta-1b treatment in patients with a first clinical event suggestive of multiple sclerosis (MS) (clinically isolated syndrome)...
  22. ncbi request reprint Oral fingolimod (FTY720) for relapsing multiple sclerosis
    Ludwig Kappos
    Department of Neurology, University Hospital, Basel, Switzerland
    N Engl J Med 355:1124-40. 2006
    ..Fingolimod (FTY720) is a new oral immunomodulating agent under evaluation for the treatment of relapsing multiple sclerosis...
  23. ncbi request reprint Alternatives to current disease-modifying treatment in MS: what do we need and what can we expect in the future?
    Ludwig Kappos
    Department of Neurology, University Hospital, Kantonsspital, 4031, Basel, Switzerland
    J Neurol 251:v57-v64. 2004
    ....
  24. ncbi request reprint Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS
    L Kappos
    Department of Neurology, University Hospitals Basel, Switzerland
    Neurology 57:1969-75. 2001
    ..The authors analyzed all data collected until closure of the double-blind study to further scrutinize the consistency of the findings...
  25. pmc MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome
    Jessica M Nielsen
    MS Center, Department of Neurology, VU Medical Center, Amsterdam, The Netherlands
    BMC Neurol 9:19. 2009
    ..Here we assess the predictive value of clinically defined dissemination in space at first presentation for time to clinically definite MS (CDMS)...
  26. ncbi request reprint Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis
    Ernst Wilhelm Radue
    Medical Image Analysis Center, University Hospital, Basel, Switzerland
    Arch Neurol 69:1259-69. 2012
    ..To assess the impact of fingolimod (FTY720) therapy on magnetic resonance imaging measures of inflammatory activity and tissue damage in patients participating in a 2-year, placebo-controlled, phase 3 study...
  27. doi request reprint Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study
    Ludwig Kappos
    University Hospital Basel, Basel, Switzerland
    Lancet 372:1463-72. 2008
    ..Oral fumarate (BG00012) might have dual anti-inflammatory and neuroprotective effects. Our aim was to assess the efficacy and safety of BG00012 in patients with relapsing-remitting multiple sclerosis...
  28. ncbi request reprint Lack of association between antimyelin antibodies and progression to multiple sclerosis
    Jens Kuhle
    Department of Research, University Hospital, Basel, Switzerland
    N Engl J Med 356:371-8. 2007
    ..An increased risk of progression to clinically definite multiple sclerosis in patients with serum antibodies against myelin oligodendrocyte glycoprotein (MOG) and myelin basic protein (MBP) has been reported...
  29. doi request reprint Contribution of cortical and white matter lesions to cognitive impairment in multiple sclerosis
    Athina Papadopoulou
    Department of Neurology, University Hospital Basel, Switzerland
    Mult Scler 19:1290-6. 2013
    ..Cortical lesions (CLs) have been reported to be a better predictor for cognitive impairment than white matter (WM) lesions in relapsing-remitting multiple sclerosis (RRMS)...
  30. doi request reprint Longitudinal gray matter changes in multiple sclerosis--differential scanner and overall disease-related effects
    Kerstin Bendfeldt
    Medical Image Analysis Center, University Hospital Basel, CH 4031 Basel, Switzerland
    Hum Brain Mapp 33:1225-45. 2012
    ..These results suggest that the effects of different scanners on longitudinal GM volume differences were rather small and thus allow pooling of MR data and subsequent combined image analysis...
  31. doi request reprint Effect of immunomodulatory medication on regional gray matter loss in relapsing-remitting multiple sclerosis--a longitudinal MRI study
    Kerstin Bendfeldt
    Medical Image Analysis Centre MIAC, University Hospital Basel, Basel, Switzerland
    Brain Res 1325:174-82. 2010
    ..This is the first longitudinal study investigating the effects of IMs on GM in RRMS. Results suggest differences in the dynamics of regional GM volume atrophy in differentially treated or untreated RRMS patients...
  32. doi request reprint Spatiotemporal distribution pattern of white matter lesion volumes and their association with regional grey matter volume reductions in relapsing-remitting multiple sclerosis
    Kerstin Bendfeldt
    Medical Image Analysis Center, University Hospital Basel, CH 4031 Basel, Switzerland
    Hum Brain Mapp 31:1542-55. 2010
    ..The different spatiotemporal distribution patterns of patients with progressive compared to patients with non-progressive WM lesions suggest differences in the dynamics of pathogenesis...
  33. pmc Global N-acetylaspartate concentration in benign and non-benign multiple sclerosis patients of long disease duration
    Lutz Achtnichts
    Departments of Neurology and Neuroradiology, University Hospital Basel, Petersgraben 4, CH 4031 Basel, Switzerland
    Eur J Radiol 82:e848-52. 2013
    ..To examine whether clinically benign multiple sclerosis patients (BMS) show similar losses of their global N-acetylaspartate (NAA) neuronal marker relative to more clinically disabled patients of similar disease duration...
  34. ncbi request reprint Antimyelin antibodies in clinically isolated syndromes correlate with inflammation in MRI and CSF
    Jens Kuhle
    Department of Neurology, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland
    J Neurol 254:160-8. 2007
    ....
  35. doi request reprint Glutamate gene polymorphisms predict brain volumes in multiple sclerosis
    Eva M M Strijbis
    Department of Neurology, VU University Medical Centre, Amsterdam, The Netherlands
    Mult Scler 19:281-8. 2013
    ..The most common approach in imaging genetics is based on mass-univariate linear modelling (MULM), which faces several limitations...
  36. pmc Preserved antigen-specific immune response in patients with multiple sclerosis responding to IFNβ-therapy
    Matthias Mehling
    Immunobiology Laboratory, Department of Biomedicine and Medical Outpatient Department, University Hospital Basel, Basel, Switzerland Department of Neurology and Clinical Neuroimmunology Laboratory Department of Biomedicine, University Hospital Basel, Basel, Switzerland
    PLoS ONE 8:e78532. 2013
    ..Data capturing antigen-specific immune responses in cohorts of subjects defined by response to IFNβ-therapy are not available...
  37. doi request reprint Progression in disability and regional grey matter atrophy in relapsing-remitting multiple sclerosis
    Louis Hofstetter
    University Hospital Basel, Switzerland
    Mult Scler 20:202-13. 2014
    ..In multiple sclerosis (MS) regional grey matter (GM) atrophy has been associated with disability progression...
  38. pmc Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis
    Iris Katharina Penner
    Department of Cognitive Psychology and Methodology, University of Basel, Missionsstrasse 60 62, Basel, Switzerland
    Mult Scler 18:1466-71. 2012
    ..Cognitive dysfunction occurs at the earliest stages of multiple sclerosis (MS), including the stage of clinically isolated syndrome (CIS)...
  39. doi request reprint Multivariate pattern classification of gray matter pathology in multiple sclerosis
    Kerstin Bendfeldt
    Medical Image Analysis Center MIAC, University Hospital Basel, CH 4031 Basel, Switzerland
    Neuroimage 60:400-8. 2012
    ....
  40. doi request reprint Midregional pro-atrial natriuretic peptide and outcome in patients with acute ischemic stroke
    Mira Katan
    Department of Endocrinology, University Hospital Basel, Basel, Switzerland
    J Am Coll Cardiol 56:1045-53. 2010
    ..The purpose of this study was to examine the prognostic value of midregional pro-atrial natriuretic peptide (MR-proANP) in patients with acute ischemic stroke...
  41. doi request reprint Antigen-specific adaptive immune responses in fingolimod-treated multiple sclerosis patients
    Matthias Mehling
    Department of Neurology, Clinical Neuroimmunology Laboratory, University Hospital Basel, Switzerland
    Ann Neurol 69:408-13. 2011
    ..These results indicate that fingolimod-treated individuals can mount vaccine-specific adaptive immune responses comparable to healthy controls...
  42. doi request reprint Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients
    Raija L P Lindberg
    Clinical Neuroimmunology Laboratory, Departments of Research and Neurology, University Hospital Basel, Switzerland
    J Neuroimmunol 194:153-64. 2008
    ..Understanding these different gene effects and their interrelationships will provide more insights into additional mechanisms of action of natalizumab and possibly allow better prediction of adverse events...
  43. doi request reprint MRI characteristics of periaqueductal lesions in multiple sclerosis
    Athina Papadopoulou
    Department of Neurology, University Hospital Basel, Petersgraben 4, CH 4031 Basel, Switzerland Medical Image Analysis Center, Schanzenstrasse 55, CH 4056 Basel, Switzerland Electronic address
    Mult Scler Relat Disord 3:542-51. 2014
    ..In multiple sclerosis (MS), periaqueductal lesions (PAL) have been described histopathologically...
  44. ncbi request reprint Discrepancies in the interpretation of clinical symptoms and signs in the diagnosis of multiple sclerosis. A proposal for standardization
    Bernard M J Uitdehaag
    Department of Neurology, VU University Medical Centre, Amsterdam, The Netherlands
    Mult Scler 11:227-31. 2005
    ..This paper describes these inconsistencies and their sources, and recommends a systematic approach that attempts to reduce the variability in interpreting clinical findings...
  45. doi request reprint Comparison between balanced steady-state free precession and standard spoiled gradient echo magnetization transfer ratio imaging in multiple sclerosis: methodical and clinical considerations
    Michael Amann
    Department of Neurology, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland Division of Diagnostic and Interventional Neuroradiology, Department of Radiology, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland Medical Image Analysis Center MIAC, Schanzenstrasse 55, 4031 Basel, Switzerland Electronic address
    Neuroimage 108:87-94. 2015
    ..This was demonstrated by the nearly perfect linearity between the NA matter MTR of both techniques as well as in the absolute MTR differences between NA matter and the respective lesions. ..
  46. doi request reprint The relationship between total and regional corpus callosum atrophy, cognitive impairment and fatigue in multiple sclerosis patients
    Ozgur Yaldizli
    Department of Neurology, University Hospital Basel, Switzerland
    Mult Scler 20:356-64. 2014
    ..The objective of this paper is to investigate the relationship between total and regional corpus callosum (CC) atrophy, neuropsychological test performance and fatigue in multiple sclerosis (MS) patients...
  47. pmc SWiss Atorvastatin and interferon Beta-1b trial In Multiple Sclerosis (SWABIMS)--rationale, design and methodology
    Christian P Kamm
    Department of Neurology, Inselspital, Bern University Hospital, and University of Bern, Switzerland
    Trials 10:115. 2009
    ....
  48. doi request reprint Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis
    Ernst Wilhelm Radue
    From the Medical Image Analysis Centre E W R, University Hospital, University of Basel, Switzerland Image Analysis Center F B, VU Medical Centre, Amsterdam, the Netherlands Departments of Medicine and Clinical Research, Neurology L K, T S and Radiology T S, Division of Neuroradiology, University Hospital, Basel, Switzerland Novartis Pharma AG D A H, A D V, P V R, Basel, Switzerland Oxford PharmaGenesis Ltd J R B, Tubney, Oxford, UK Novartis Pharmaceuticals Corporation G F, East Hanover, NJ and Neurological Institute J A C, Cleveland Clinic, OH
    Neurology 84:784-93. 2015
    ..We investigated the determinants and clinical correlations of MRI-detected brain volume loss (BVL) among patients with relapsing-remitting multiple sclerosis from the phase 3 trials of fingolimod: FREEDOMS, FREEDOMS II, and TRANSFORMS...
  49. doi request reprint A highly sensitive electrochemiluminescence immunoassay for the neurofilament heavy chain protein
    Jens Kuhle
    Clinical Neuroimmunology, Neurology and Department of Biomedicine, University Hospital Basel, Switzerland
    J Neuroimmunol 220:114-9. 2010
    ..Electrochemiluminescence (ECL) based assays are known to be of superior sensitivity and require less sample volume than conventional ELISAs...
  50. doi request reprint Relevance of spinal cord abnormalities to clinical disability in multiple sclerosis: MR imaging findings in a large cohort of patients
    Carsten Lukas
    Department of Diagnostic and Interventional Radiology and Nuclear Medicine, St Josef Hospital, Ruhr University Bochum, Gudrunstr 56, 44791 Bochum, Germany Departments of Neurology, Radiology, Epidemiology and Biostatistics, Anatomy and Neurosciences, Section of Clinical Neuroscience, and Physics and Medical Technology, MS Center Amsterdam, VU University Medical Center, Amsterdam, the Netherlands Fraunhofer MEVIS, Institute for Medical Image Computing, Bremen, Germany
    Radiology 269:542-52. 2013
    ..To determine whether spinal cord atrophy differs among disease subtypes in multiple sclerosis (MS) and whether it offers diagnostic and clinical correlative information beyond that provided by other magnetic resonance (MR) imaging markers...
  51. pmc Unraveling natalizumab effects on deregulated miR-17 expression in CD4+ T cells of patients with relapsing-remitting multiple sclerosis
    Maria Meira
    Clinical Neuroimmunology, Departments of Biomedicine and Neurology, University Hospital Basel, Hebelstrasse 20, 4031 Basel, Switzerland
    J Immunol Res 2014:897249. 2014
    ..These findings support an effect of natalizumab on expression of specific miRNA and subsequent expression of genes involved in proliferation and control of the cell cycle...
  52. pmc Subcortical brain segmentation of two dimensional T1-weighted data sets with FMRIB's Integrated Registration and Segmentation Tool (FIRST)
    Michael Amann
    Department of Neurology, University Hospital Basel, Petersgraben 4, Basel 4031, Switzerland Division of Diagnostic and Interventional Neuroradiology, Department of Radiology, Petersgraben 4, Basel 4031, Switzerland
    Neuroimage Clin 7:43-52. 2015
    ..This forms the basis for the application of FIRST in large 2D MRI data sets of clinical trials in order to determine the impact of therapeutic interventions on DGM atrophy in MS. ..
  53. pmc White matter lesion filling improves the accuracy of cortical thickness measurements in multiple sclerosis patients: a longitudinal study
    Stefano Magon
    Department of Neurology, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland
    BMC Neurosci 15:106. 2014
    ....
  54. doi request reprint Label-fusion-segmentation and deformation-based shape analysis of deep gray matter in multiple sclerosis: the impact of thalamic subnuclei on disability
    Stefano Magon
    Department of Neurology, University Hospital Basel, Switzerland Medical Image Analysis Center, University Hospital Basel, Switzerland
    Hum Brain Mapp 35:4193-203. 2014
    ..The results stress the importance of ventral thalamic nuclei in this respect...
  55. pmc Cerebellar abnormalities contribute to disability including cognitive impairment in multiple sclerosis
    Katrin Weier
    Department of Neurology, University Hospital Basel, Basel, Switzerland
    PLoS ONE 9:e86916. 2014
    ..However, this contribution does not seem to be independent of, and may even be dominated by wider spread MS pathology as reflected by nBV and T2 LV. ..
  56. doi request reprint T-cell response against varicella-zoster virus in fingolimod-treated MS patients
    Meret E Ricklin
    Clinical Neuroimmunology, Department of Biomedicine, University of Basel, Switzerland
    Neurology 81:174-81. 2013
    ..To study the immune response against varicella-zoster virus (VZV) in patients with multiple sclerosis before and during fingolimod therapy...
  57. doi request reprint Evaluation of a new approach for semi-automatic segmentation of the cerebellum in patients with multiple sclerosis
    Katrin Weier
    Department of Neurology, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland
    J Neurol 259:2673-80. 2012
    ..Our matched-pair analysis between MS patients and healthy volunteers suggests that the method is sensitive and reliable in detecting cerebellar atrophy in MS...
  58. doi request reprint Balance control in multiple sclerosis: correlations of trunk sway during stance and gait tests with disease severity
    Sharissa H A Corporaal
    Department of Oto Rhino Laryngology, University Hospital, Basel, Switzerland
    Gait Posture 37:55-60. 2013
    ..To investigate which measures of trunk sway taken during stance and gait tasks are best correlated with Expanded Disability Status Scale (EDSS) scores of multiple sclerosis (MS) patients...
  59. doi request reprint Spatiotemporal distribution of white matter lesions in relapsing-remitting and secondary progressive multiple sclerosis
    Lukas Filli
    Medical Image Analysis Center, University Hospital Basel, Basel, Switzerland
    Mult Scler 18:1577-84. 2012
    ..Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system. MS lesions show a typical distribution pattern and primarily affect the white matter (WM) in the periventricular zone and in the centrum semiovale...
  60. pmc Mannose-binding lectin deficiency is associated with smaller infarction size and favorable outcome in ischemic stroke patients
    Michael Osthoff
    Laboratory of Clinical Immunology, Department of Biomedicine and Clinic for Internal Medicine, University Hospital Basel, Basel, Switzerland
    PLoS ONE 6:e21338. 2011
    ....
  61. doi request reprint Altered expression of miR-17-5p in CD4+ lymphocytes of relapsing-remitting multiple sclerosis patients
    Raija L P Lindberg
    Clinical Neuroimmunology, Department of Biomedicine and Neurology, University Hospital Basel, Basel, Switzerland
    Eur J Immunol 40:888-98. 2010
    ..Our findings support the role of miRNA-dependent regulatory mechanisms in the immunopathogenesis of MS...
  62. doi request reprint Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis
    Jens Kuhle
    From the Neuroimmunology Unit J K, G D, G G, Blizard Institute, Barts and the London School of Medicine and Dentistry, London, UK Neurology, Departments of Medicine, Clinical Research and Biomedicine J K, J L, L K, and the Medical Image Analysis Center MIAC E W R, University Hospital, Basel, Switzerland Novartis Pharmaceuticals Corporation T S, Y C, G F, East Hanover, NJ Novartis Pharma AG F D, Basel, Switzerland and Novartis Healthcare Pvt Ltd A S, Hyderabad, India
    Neurology 84:1639-43. 2015
    ..Changes in NfL levels were also correlated with relapse and MRI outcomes...
  63. doi request reprint Combined evoked potentials as markers and predictors of disability in early multiple sclerosis
    Regina Schlaeger
    Department of Neurology, University Hospital Basel, Switzerland
    Clin Neurophysiol 123:406-10. 2012
    ..To prospectively assess combined evoked potentials (EP) as markers and predictors of the disease course of early MS over 3 years...
  64. pmc Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis
    Goeril Karlsson
    From Novartis Pharma AG G Karlsson, P H, W C, Basel, Switzerland Novartis Pharmaceuticals Corporation G F, X Z, East Hanover, NJ Motherisk Program G Koren, Hospital for Sick Children, Toronto, Canada Neurological Institute J A C, Cleveland Clinic, OH and Neurology and Department of Biomedicine L K, University Hospital, Basel, Switzerland
    Neurology 82:674-80. 2014
    ..To report outcomes of pregnancies that occurred during the fingolimod clinical development program...
  65. doi request reprint Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings
    Ludwig Kappos
    Neurology, Department of Medicine, Clinical Research and Biomedicine, University Hospital, Petersgraben 4, CH 4031 Basel, Switzerland Electronic address
    Mult Scler Relat Disord 3:494-504. 2014
    ..Fingolimod 0.5mg once daily is the first approved oral therapy for relapsing multiple sclerosis (MS)...
  66. doi request reprint MiR-126: a novel route for natalizumab action?
    Maria Meira
    University Hospital Basel, University of Basel, Switzerland
    Mult Scler 20:1363-70. 2014
    ..Our previous low-density array studies reveal differential miR-126 expression in the CD4(+)T cells of untreated relapsing-remitting MS (RRMS) patients. Here, we investigated miR-126 expression in natalizumab-treated patients...
  67. doi request reprint Lesion-to-ventricle distance and other risk factors for the persistence of newly formed black holes in relapsing-remitting multiple sclerosis
    Athina Papadopoulou
    Department of Neurology, University Hospital Basel, Switzerland
    Mult Scler 20:322-30. 2014
    ..This process may depend on the distance between the lesion and the SVZ...
  68. ncbi request reprint Therapy-induced plasticity of cognitive functions in MS patients: insights from fMRI
    Iris Katharina Penner
    Department of Cognitive Psychology and Methodology, University of Basel, Switzerland
    J Physiol Paris 99:455-62. 2006
    ..Results of a study on correlating the effects of cognitive training with changes in brain organization in patients with mild to severe cognitive impairment will be reported...
  69. doi request reprint Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis
    Henrik Gensicke
    Neurology, Department of Medicine, University Hospital Basel, Basel, Switzerland
    CNS Drugs 26:11-37. 2012
    ....
  70. doi request reprint Fingolimod for multiple sclerosis: mechanism of action, clinical outcomes, and future directions
    Matthias Mehling
    Department of Neurology and Department of Biomedicine, University Hospital Basel, Petersgraben, Switzerland
    Curr Neurol Neurosci Rep 11:492-7. 2011
    ..Overall, in clinical studies fingolimod was well tolerated and had a favorable safety profile. In follow-up studies with continuous fingolimod, treatment showed sustained efficacy while being well tolerated...
  71. doi request reprint Combined visual and motor evoked potentials predict multiple sclerosis disability after 20 years
    Regina Schlaeger
    Department of Neurology, University Hospital Basel, Switzerland
    Mult Scler 20:1348-54. 2014
    ..The development of predictors of multiple sclerosis (MS) disability is difficult due to the complex interplay of pathophysiological and adaptive processes...
  72. doi request reprint Electrophysiological markers and predictors of the disease course in primary progressive multiple sclerosis
    Regina Schlaeger
    Department of Neurology, University Hospital Basel, Switzerland
    Mult Scler 20:51-6. 2014
    ..Currently no valid surrogate marker exists for primary progressive multiple sclerosis (PPMS)...
  73. ncbi request reprint Relation between functional brain imaging, cognitive impairment and cognitive rehabilitation in patients with multiple sclerosis
    Iris Katharina Penner
    University of Basel, Dept of Cognitive Psychology and Methodology, Missionsstr 60 62, 4055, Basel, Switzerland
    J Neurol 254:II53-7. 2007
    ....
  74. doi request reprint Evolution of MS lesions to black holes under DNA vaccine treatment
    Athina Papadopoulou
    Department of Neurology, University Hospital Basel, Petersgraben, Basel, Switzerland
    J Neurol 259:1375-82. 2012
    ..01). Although we found no overall reduction of the risk for PBH in treated patients, there may be an effect of low-dose BHT-3009, depending on the patients' pre-treatment immune responses...
  75. doi request reprint 3D GRASE arterial spin labelling reveals an inverse correlation of cortical perfusion with the white matter lesion volume in MS
    Michael Amann
    Department of Neuroradiology, University Hospital Basel, Switzerland
    Mult Scler 18:1570-6. 2012
    ..We hypothesized that in multiple sclerosis (MS) patients, reduced cortical perfusion is associated with chronic white matter injury...
  76. doi request reprint Biplanar MRI for the assessment of the spinal cord in multiple sclerosis
    Katrin Weier
    Department of Neurology, University Hospital Basel, Basel, Switzerland
    Mult Scler 18:1560-9. 2012
    ..To investigate the entire spinal cord (SC) of multiple sclerosis (MS) patients with biplanar MRI and to relate these MRI findings to clinical functional scores...
  77. doi request reprint Copeptin: a novel, independent prognostic marker in patients with ischemic stroke
    Mira Katan
    Department of Endocrinology, University Hospital Basel, Switzerland
    Ann Neurol 66:799-808. 2009
    ..Vasopressin is a stress hormone. Its production rate is mirrored in circulating levels of copeptin, a fragment of provasopressin. We evaluated the prognostic value of copeptin in acute stroke patients...
  78. ncbi request reprint Atrophy is detectable within a 3-month period in untreated patients with active relapsing remitting multiple sclerosis
    Martin Hardmeier
    MS MRI Evaluation Centre Basel, Basel, Switzerland
    Arch Neurol 60:1736-9. 2003
    ..The time course and pathologic mechanisms of atrophy development are not well understood. Significant atrophy was reported to occur within 9 to 12 months in relapsing remitting MS...
  79. ncbi request reprint Rate of brain atrophy in relapsing MS decreases during treatment with IFNbeta-1a
    M Hardmeier
    MS MRI Evaluation Centre Basel, University Hospitals Basel, Switzerland
    Neurology 64:236-40. 2005
    ..To determine the time course of brain atrophy during treatment with once-weekly IM interferon beta-1a (IFNbeta-1a)...
  80. doi request reprint The Fatigue Scale for Motor and Cognitive Functions (FSMC): validation of a new instrument to assess multiple sclerosis-related fatigue
    I K Penner
    Department of Cognitive Psychology and Methodology, University of Basel, Basel, Switzerland
    Mult Scler 15:1509-17. 2009
    ..In conclusion, the FSMC is a new scale that has undergone validation based on a large sample of patients and that provides differential quantification and graduation of cognitive and motor fatigue...
  81. doi request reprint Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis
    M Mehling
    Department of Neurology, University Hospitals Basel, Petersgraben 4, CH 4031 Basel, Switzerland
    Neurology 75:403-10. 2010
    ..In this study, we determined the phenotype and frequency of Th17 cells in blood of untreated, FTY720-treated, and interferon-beta (IFNbeta)-treated patients with MS and healthy donors...
  82. pmc Improved characterization of visual evoked potentials in multiple sclerosis by topographic analysis
    Martin Hardmeier
    Department of Neurology, Hospital of the University of Basel, Petersgraben 4, 4031, Basel, Switzerland
    Brain Topogr 27:318-27. 2014
    ..TVEP is a reliable, valid, and sensitive method of objectively quantifying pathological VEP in particular. In combination with other EP modalities, tVEP may improve the monitoring of disease course in MS...
  83. doi request reprint Teriflunomide for oral therapy in multiple sclerosis
    Athina Papadopoulou
    Department of Neurology, University Hospital of Basel, Switzerland
    Expert Rev Clin Pharmacol 5:617-28. 2012
    ..It may be a good alternative for patients wishing to have an oral treatment with relatively large data regarding long-term safety...
  84. ncbi request reprint Transcriptional profiling of multiple sclerosis: towards improved diagnosis and treatment
    Raija L P Lindberg
    Outpatient Clinic Neurology Neurosurgery and Department of Research, Pharmazentrum University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland
    Expert Rev Mol Diagn 6:843-55. 2006
    ..The emerging potential of microarray technology to define gene signatures, diagnostic and prognostic markers for disease course, and treatment response in multiple sclerosis will be discussed...
  85. ncbi request reprint Vancouver Consortium of MS Centers' Magnetic Resonance Imaging Guidelines
    Ernst Wilhelm Radue
    Kantonsspital Basel, Abtl Neuroradiologie, 4031 Basel, Switzerland
    Int MS J 10:131-3. 2003
    ..MRI aids our understanding of MS and management of patients...
  86. doi request reprint Association of regional gray matter volume loss and progression of white matter lesions in multiple sclerosis - A longitudinal voxel-based morphometry study
    Kerstin Bendfeldt
    Department of Neuroradiology, University Hospital Basel, Switzerland
    Neuroimage 45:60-7. 2009
    ..The present study suggests that the progression of regional GM volume reductions is associated with WM lesion progression and occurs predominantly in fronto-temporal cortical areas...
  87. doi request reprint Working memory training in patients with multiple sclerosis - comparison of two different training schedules
    Annamarie Vogt
    Department of Cognitive Psychology and Methodology, University of Basel, Basel CH 4055, Switzerland
    Restor Neurol Neurosci 27:225-35. 2009
    ..Evaluation of two different training schedules of a computer based working memory training (BrainStim) in patients with multiple sclerosis (MS)...
  88. ncbi request reprint Multiple sclerosis as a generalized CNS disease--comparative microarray analysis of normal appearing white matter and lesions in secondary progressive MS
    Raija L P Lindberg
    Clinical Neuroimmunology Laboratory, Departments of Research and Neurology, University Hospitals Basel, Pharmazentrum, Klingelbergstrasse 50, CH 4056 Basel, Switzerland
    J Neuroimmunol 152:154-67. 2004
    ....
  89. doi request reprint Altered functional adaptation to attention and working memory tasks with increasing complexity in relapsing-remitting multiple sclerosis patients
    Michael Amann
    Department of Neuroradiology, University Hospital Basel, CH 4031 Switzerland
    Hum Brain Mapp 32:1704-19. 2011
    ..Our results indicate that, in MS, functional adaptation patterns can be found which precede clinical evidence of apparent cognitive decline...
  90. ncbi request reprint Swallowing abnormalities in multiple sclerosis: correlation between videofluoroscopy and subjective symptoms
    W Wiesner
    Institute of Diagnostic Radiology, University Hospital of Basel, Petersgraben 4, 4031 Basel, Switzerland
    Eur Radiol 12:789-92. 2002
    ..Swallowing abnormalities seem to be much more frequent in patients with MS than generally believed and they may easily be missed clinically as long as the patients do not aspirate...
  91. ncbi request reprint [Neurological complications of HIV infection. Review: new diagnostic, therapeutic and prognostic aspects]
    A J Radziwill
    Neurologische Universitätsklinik und Poliklinik, Kantonsspital Basel
    Schweiz Med Wochenschr 130:457-70. 2000
    ..The prognosis of different HIV-associated neurological diseases has considerably improved, as recently shown in the case, for example, of progressive multifocal leucoencephalopathy...
  92. doi request reprint Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis
    J Kuhle
    Department of Biomedicine and Neurology, University Hospital Basel, CH 4031 Basel, Switzerland
    Neurology 76:1206-13. 2011
    ..We sought to discover whether CSF levels of neurofilament heavy chain protein (NfH(SMI35)) correlate with disability, disease activity, or specific stages of MS...
  93. pmc MS quality of life, depression, and fatigue improve after mindfulness training: a randomized trial
    P Grossman
    Department of Psychosomatic Medicine, Division of Internal Medicine, University Hospital Basel, Hebelstrasse 2, Basel, Switzerland
    Neurology 75:1141-9. 2010
    ..We examined effects of a mindfulness-based intervention (MBI) compared to usual care (UC) upon HRQOL, depression, and fatigue among adults with relapsing-remitting or secondary progressive MS...
  94. ncbi request reprint Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group
    L Kappos
    Department of Neurology, Kantonsspital, Basel, Switzerland
    Lancet 353:964-9. 1999
    ..To investigate the prognostic value of gadolinium-enhanced MRI, we did a meta-analysis of longitudinal MRI studies...
  95. ncbi request reprint Fatigue in multiple sclerosis: relation to depression, physical impairment, personality and action control
    I K Penner
    Department of Cognitive Psychology and Methodology, University of Basel, Switzerland
    Mult Scler 13:1161-7. 2007
    ..Decreased levels of action control imply attentional and motivational deficits and were only found in fatigued MS patients. Our study indicates that motivational disturbances might be specific for MS related fatigue...
  96. doi request reprint [Stress-related vertical double vision and ptosis]
    A M Palmowski-Wolfe
    Augenklinik, Universitatsspital Basel, Basel, Schweiz
    Ophthalmologe 106:52-4. 2009
    ..This treatment approach led to a reduction of tumor volume in our patient as well as clinical improvement followed by stabilization...
  97. doi request reprint Neuropsychological dysfunction, depression, physical disability, and coping processes in families with a parent affected by multiple sclerosis
    M M Ehrensperger
    Memory Clinic, Department of Geriatrics, University Hospital Basel, Switzerland
    Mult Scler 14:1106-12. 2008
    ..Most studies analyzing factors that influence coping abilities in families with a member affected with MS used questionnaires to assess this ability...
  98. doi request reprint Retinal vessels in patients with multiple sclerosis: baseline diameter and response to flicker light stimulation
    K Gugleta
    University Eye Clinic Basel, Basel, Switzerland
    Klin Monbl Augenheilkd 226:272-5. 2009
    ..Transparency of ocular media enables the precise quantitative analysis of vessels of retina, a neuronal tissue which can be affected by multiple sclerosis (MS)...
  99. doi request reprint Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis
    Ernst Wilhelm Radue
    Medical Image Analysis Center, University Hospital Basel, Schanzenstrasse 55, 1st Floor, CH 4031, Basel, Switzerland
    J Neurol Sci 292:28-35. 2010
    ....
  100. doi request reprint Non-communicating syringomyelia: a feature of spinal cord involvement in multiple sclerosis
    Katrin Weier
    Department of Neurology Neuroradiology, University Hospital Basel, Petersgraben 4, CH 4031 Basel, Switzerland
    Brain 131:1776-82. 2008
    ..We confirm that NCS may occur in MS patients with spinal cord pathology. It can be a subtle finding without clinical correlates. Syrinx formations are more likely to be a consequence of MS cord pathology than a coincidental finding...
  101. ncbi request reprint Retraining attention in MS
    Iris Katharina Penner
    Department of Cognitive Psychology and Methodology, University of Basel, Missionsstr 60 62, 4055 Basel, Switzerland
    J Neurol Sci 245:147-51. 2006
    ....